Phase II study of cetuximab plus 5-FU/LV for unresectable colorectal cancer

ABSTRACT: Interventions: cetuximab plus 5-FU/LV Primary outcome(s): response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Colorectal Cancer

PROVIDER: 2624880 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR